Caribou Biosciences, Inc.

CRBU Healthcare Biotechnology

Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue fell 43.8%, EPS grew 58.6% and free cash flow fell 33.2%, each against the same quarter a year earlier.

0.47 0.00 0.00%
Market cap
$49.8M
P/E
0.0×
Fwd P/E
−1.6×
Dividend yield
—
F-score
3/9
Altman Z
−5.00
Beneish M
−3.93
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
17.71 16.26 13.31 23.39
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(7.80) (6.75) (7.13) (8.63)
P/B ratio
1.81 1.79 1.22 1.53
EV/Sales
6.52 5.76 0.82 7.54
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(0.49) (0.63) (0.08) (0.55)
Current Ratio
6.49 6.22 5.71 5.54
Net Debt/EBITDA
4.54 4.54 4.99 5.08
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(61.36%) (74.74%) (100.00%) (72.96%)
Free Cash Flow Yield
(74.71%) (55.80%) (75.66%) (58.76%)
Free Cash Flow per Share
0.62 (0.28) (0.22) (1.59)
Book value per Share
0.97 1.06 1.31 1.52
Free Cash Flow
62.80 (27.06) (20.61) (147.93)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates